FDA Approval of a New Treatment: What’s Next for the Alzheimer’s Community?

46:11
 
Share
 

Manage episode 294719665 series 41856
By UsAgainstAlzheimer's. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

The Food and Drug Administration (FDA) has approved aducanumab as a new treatment for early-stage Alzheimer’s disease, and this AlzTalks explores what this means for the Alzheimer’s community.

Host Meryl Comer talked about the drug treatment with Biogen’s Samantha Budd Haeberlein, PhD, SVP, Head of Neurodegeneration Development and Karin Hellsvik, Head, External Communications and Patient Advocacy, and had a conversation about the decision with George Vradenburg, chairman and co-founder of UsAgainstAlzheimer’s; Russ Paulsen, UsA’s chief operating officer; and Jason Resendez, executive director of the UsAgainstAlzheimer’s Center for Brain Health Equity.

Meryl Comer also spoke about this new drug with advocates Jim and Geri Taylor. Geri, who lives with Alzheimer’s disease, participated in the clinical trial for this therapy.

Support the show (https://www.usagainstalzheimers.org/ways-donate)

87 episodes